Global Non-Insulin Therapies Market, By Product (Oral {Thiazolidinediones (TZDs), Insulin secretagogues, Alpha-glucosidase inhibitors (AGIs), Sulfonylureas, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, Glinides/Meglitinides, Metformin, Biguanides, & Others} Injectable {Glucagon-like peptide-1 (GLP-1) agonists, Amylin Agonists, & Others}), By Distributor (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, & Others),By Region (U.S., Canada, UK, Germany, France, Spain, Italy, Russia, China, India, Japan, Brazil, Mexico, South Africa, Saudi Arabia), Industry Trends, Market Estimation & Forecast, 2019 – 2025


Check Today's Best Price

$3500 Buy Now
Non-insulin therapies market valued over USD 60,783 million in 2018 and is estimated to expand at a CAGR of over 6.5% during the forecast period.
  • Market Overview

    Non-insulin therapies market valued over USD 60,783 million in 2018 and is estimated to expand at a CAGR of over 6.5% during the forecast period.

    Global Non-Insulin Therapies Market, USD million, (2015-2025)

    Global Non-Insulin Therapies Market, USD million, (2015-2025)-1



    The rising number of diabetes incidence and expanding prevalence of the same is the most alarming concerns in the healthcare industry worldwide. According to the International Diabetes Federation, more than 317 million people have diabetes. Additionally, 187 million have not been diagnosed. To address appalling diabetes prevalence, major pharmaceutical companies are in the process of developing novel drugs candidates for better efficacy in diabetes treatment. Along with traditional insulin therapies, non-insulin therapies are quickly becoming first-line therapies for diabetes. However, insulin therapies still occupy majorly used for diabetes one treatment worldwide. On the other side, non-insulin therapies are essentially first-line therapies for diabetes type 2.

    Technological advancements play a paramount role in forming and shaping the non-insulin therapy market. Some of the major drugs in the market, such as GLP-1 agonists and DPP4 inhibitors are available for more than a decade; however, recently approved SGLT2 inhibitors in 2013 are rapidly gaining ground. A number of non-insulin drugs have made them into blockbuster charts since their approval; for example, GLP-1 agonist Victoza, JANUVIA/JANUMET (DPP4 inhibitors and INVOKANA /INVOKAMET a SGLT2 inhibitor.

    The market is strongly driven by the aforementioned drugs; however, as patient expiration for a number of drugs is lined up, the non-insulin therapy market growth is anticipated to slow down during the forecast period. Victoza is poised to face patent expiration by the end of 2022.

    Product Market Overview

    Sulfonylureas, alpha-glucosidase, glinides etc. are the first class of non-insulin drugs in the market. However, lately, new world drugs classes such as GLP-1 agonists and DPP4 inhibitors have become a mainstream candidate in diabetes type 2 treatment. As a result, the GLP-1 agonists market is estimated to grow with a robust CAGR over the forecast period.

    Oral non-insulin therapies for diabetes type 2 hold lions shares in the market, accounting for nearly 90% of the market share. Easy consumption and availability of oral drugs attribute to rapid market growth. However, over the forecast period, injectable non-insulin therapy will witness the fastest growth rate of over 7% CAGR from 2019-2025.

    Regional Market Overview

    U.S non-insulin therapies market accounted for the largest market share worldwide. Technological advancement and adoption, high spending on diabetes care by patients and healthcare, increasing incidence of diabetes type 2 are some of the major factors driving the U.S market growth. According to international diabetes federation, in the U.S, more than 17 thousand new cases of diabetes emerge every year.

    The Asia Pacific non-insulin therapies market is poised to expand with a robust CAGR of over 7% during the forecast timeframe. Diabetes prevalence is rapidly increasing in Asian countries. Diabetes, which was considered as the disease of abundance exclusively seen in industrialized nations, is alarmingly becoming a major hurdle for healthcare systems in developing countries of Asia such as India and China. Moreover, smaller economies, such as Taiwan and other south Asia countries, will experience significant growth in the diabetes care market. Taiwan is one of the fastest-growing market place.

    China non-insulin therapies market is poised to expand at an exceptional rate due to increasing incidence of diabetes type 2, healthcare sectors expansion, and development of new facilities and rising awareness and spending related to diabetes care cities. A large unmet need for diabetes type 2 care is waiting to be addressed by the advanced introduction of advanced drugs in the industry. As a result, the market is expected to witness growth, especially in tier 1 cities of the country. In the near future, as per estimates, China’s market is most likely to outpace European market.

    Key Industry Participants

    Eurofarma Laboratory, Merck Sharp & Dohme Group, Eli Lilly, Pfizer, AstraZeneca, Novo Nordisk, Sanofi are the major industry participants in global non-insulin therapies market. New technology-based products, geographic expansion, mergers and acquisitions are some of the major strategies implemented by companies to gain market share.

    By Product

    • Oral
      • Thiazolidinediones
      • Insulin Secretagogues
      • Alpha-glucosidase inhibitors
      • Sulfonylureas
      • Dipeptidyl peptidase-4 (DPP-4) inhibitors
      • Sodium-Glucose cotransporter-2 (SGLT2)
      • Glinides/Meglitinides
      • Metformin
      • Biguanides
      • Others
    • Injectable
      • Glucagon-like peptide (GLP-1) agonists
      • Amylin Agonists
      • Others
    • By Distribution channel
      • Hospitals
      • Retail pharmacies
      • Others

    By region:

    • North America
      • The U.S.
      • Canada
      • Rest of North America
    • Europe
      • UK
      • France
      • Germany
      • Spain
      • Italy
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
      • Rest of Asia Pacific
    • The Middle East and Africa
      • Saudi Arabia
      • South Africa
      • Rest of the Middle East and Africa
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America


    Increasing incidence of diabetes type 2 worldwide

    Technological advancement in diabetes drugs

    Rising diabetes diagnosis rates


    The high cost of therapy

    Lack of awareness in developing regions


    Huge untapped market potential in emerging economies

  • Table of Content

  • Key Industry Participants

    • Eurofarma Laboratory
    • Merck Sharp & Dohme Group
    • Eli Lilly
    • Pfizer
    • AstraZeneca
    • Novo Nordisk
    • Sanofi

    • Keep your personal detail safe with us. Privacy Policy
      This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.